Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Keen Kevzara Pricing Will Be Sanofi’s Best Hope After Speedy NICE Nod

A three-month turnaround from approval in Europe for Sanofi’s rheumatoid arthritis drug to recommendation in England is pretty quick. The firm will need to maintain keen pricing in a competitive field.

Immune Disorders Reimbursement

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests

Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.

Biosimilars Pricing Debate

Biosimilar Post-Approval Change Guidance Coming From US FDA

Guidance, which is undergoing clearance, will address other products as well and might be released by the end of the year.

Manufacturing Biosimilars
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register